• Oral presentation: APL-1702 long-term efficacy and safety for cervical histologic high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase Ⅲ global study

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1, on March 17, 2024)

The Society of Gynecologic Oncology (SGO)'s Annual Meeting on Women's Cancer is one of the most prominent global gatherings in the field of gynecologic oncology, bringing together thousands of top experts and scholars from around the world. It showcases the latest research advancements and best clinical practices in the field of gynecologic oncology.

Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-results-of-the-international-multicenter-phase-iii-clinical-study-for-1702-a-non-surgical-treatment-for-cervical-hsil-at-the-2024-sgo-annual-meeting/

Cevira is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix. Photocure developed Cevira through Phase 1 and Phase 2 trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019. Asieris is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com